The U.S. Food and Drug Administration (FDA) has approved Revtorpyk (gedatolisib), developed by Celcuity, for certain patients with advanced or... Read more
Category: Uncategorized
BEYOND THE $1.5 BILLION DEAL: WHY ASTRAZENECA’S LATEST CHINA BET SIGNALS A NEW ERA IN GLOBAL ONCOLOGY
AstraZeneca has entered into an exclusive global licensing agreement with China's Dizal Pharmaceutical for Zegfrovy (sunvozertinib), an oral targeted therapy... Read more
WHEN TAX COMPLIANCE BECOMES A BOARDROOM ISSUE: WHAT DƯỢC HẬU GIANG’S CASE SIGNALS FOR VIETNAM’S PHARMACEUTICAL INDUSTRY
While the financial impact is relatively modest for a company of DHG's scale, the incident reflects a broader trend of... Read more
BEYOND WEIGHT LOSS: WHY FRAILTY MONITORING MAY DEFINE THE NEXT ERA OF GLP-1 THERAPIES
The rapid expansion of GLP-1 receptor agonists has fundamentally reshaped obesity management, but a new study suggests that the next... Read more
CYLOSPORIASIS CASES SURGE IN THE U.S.: A PUBLIC HEALTH SIGNAL FOR FOOD SAFETY, DIAGNOSTICS, AND HEALTHCARE RESILIENCE
The United States is experiencing a significant increase in reported cyclosporiasis cases, a foodborne parasitic infection caused by Cyclospora cayetanensis.... Read more
HANOI TIGHTENS FOOD SAFETY ENFORCEMENT AS SCHOOL MEAL SUPPLY CHAINS COME UNDER SCRUTINY
Hanoi authorities have intensified oversight of school meal supply chains after inspections identified multiple violations involving food suppliers serving educational... Read more
FDA’S APPROVAL OF AT HOME LEQEMBI ADMINISTRATION COULD RESHAPE ALZHEIMER’S CARE DELIVERY
The U.S. Food and Drug Administration (FDA) has approved an at home starting dose option for Leqembi (lecanemab), allowing eligible... Read more
NOVO NORDISK ADVANCES ITS RARE DISEASE AMBITIONS WITH POSITIVE PHASE III HEMOPHILIA DATA
Novo Nordisk has announced positive results from the Phase III FRONTIER4 extension study, reinforcing the long term safety and efficacy... Read more
ASTRAZENECA’S LATEST LICENSING DEAL UNDERSCORES THE RISE OF CHINA AS A GLOBAL ONCOLOGY INNOVATION HUB
AstraZeneca has expanded its oncology pipeline through a new licensing agreement with Dizal Pharmaceutical, securing global rights outside mainland China... Read more









